SLC35E1 Inhibitors
Chemical inhibitors of the SLC35E1 protein function through various mechanisms that disrupt the enzymatic activities and processes essential for the protein's role in nucleotide sugar transport. Suramin, for instance, acts by inhibiting enzymes responsible for phosphate group transfer, a critical process that likely plays a role in SLC35E1's function. This inhibition can decrease the transport efficacy of SLC35E1. Similarly, AMP-PNP, being a non-hydrolysable ATP analogue, can interfere with ATP-dependent enzymes, potentially affecting the energy-dependent transport mechanism that SLC35E1 utilizes. Benzyl-α-GalNAc, on the other hand, disrupts O-glycosylation, which could lead to a reduction in the availability of glycosylated substrates for SLC35E1, thereby functionally inhibiting its activity.
Other chemicals affect the glycosylation process, which is an indirect but crucial aspect of SLC35E1's function. Tunicamycin inhibits the initial step of glycosylation in the endoplasmic reticulum, thus could decrease the availability of substrates for SLC35E1. Compounds like Swainsonine, Castanospermine, Deoxynojirimycin, Deoxymannojirimycin, and Kifunensine inhibit various glycosidases such as mannosidase I and II, and glucosidase. These inhibitions can lead to the accumulation of misprocessed glycoproteins, potentially overloading the glycosylation machinery and indirectly diminishing SLC35E1's transport capacity. Similarly, NB-DNJ, by inhibiting glucosylceramide synthase, can impair the synthesis of glycosphingolipids, which are important for glycosylation pathways involving SLC35E1. Lastly, compounds like Brefeldin A and Monensin disrupt the Golgi apparatus's function by disturbing its structure and pH gradient, respectively.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin inhibits various enzymes that facilitate the transfer of phosphate groups, which is a process that SLC35E1 may rely on for its proper functioning in nucleotide sugar transport. By blocking this enzymatic activity, suramin can reduce the efficacy of SLC35E1's transport mechanism. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits the initial step of glycosylation in the endoplasmic reticulum, which could decrease the availability of glycosylated substrates for SLC35E1, thereby functionally inhibiting its transport activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, which could lead to a buildup of misprocessed glycoproteins, potentially overloading the glycosylation machinery and indirectly inhibiting SLC35E1's function in transporting nucleotide sugars. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidase, an enzyme involved in N-linked glycosylation, which could disrupt the processing and transport of glycoproteins, indirectly diminishing the function of SLC35E1. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidases, which can lead to improper glycoprotein synthesis and maturation, potentially impacting the proper function of SLC35E1 by reducing the demand for its substrate transport activities. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin inhibits mannosidase I, which could impede the trimming of glycoproteins, indirectly influencing the activity of SLC35E1 by disrupting the normal glycosylation process. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
Benzyl-α-GalNAc is an inhibitor of O-glycosylation; its presence could disturb the balance of glycosylated products, possibly leading to a functional inhibition of SLC35E1 by reducing the availability of its substrates. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits mannosidase I, which could affect the maturation of glycoproteins and indirectly inhibit the functionality of SLC35E1 by altering its substrate specificity or availability. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, which could indirectly inhibit SLC35E1 by preventing the proper localization of this transporter or by altering the glycosylation pathway which it is part of. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts the Golgi's pH gradient, which is crucial for its function. This disruption can indirectly inhibit SLC35E1 by impairing the environment necessary for its nucleotide sugar transport activity. | ||||||